N/A N=24 Human Comedogenicity Test
Comedogenicity
Primary: Microcomedone Score of Follicular Biopsies — 0.84; 0.97 microcomedone score — p=0.274
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=59 Cumulative Irritation Potential of 828 Ointment
Healthy Volunteers
Primary: Presence of Cumulative Irritation — 163.0; 109.0; 2073.0 units on a scale
Phase 3 N=120 An Efficiency of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel in Acne
Acne
Primary: Reduction of Undesirable Effects — 26; 38; 35; 10 participants — p=0.001
N/A N=20 A Study to Document the Effect of Petrolatum on Innate Immune Responses in the Skin
Skin Disease
Primary: Expression Levels of Antimicrobial Peptides in Samples of Normal Appearing Skin and Skin Subjected to Occlusion With and Without Petrolatum. — 9.12; 7.025; 5.415; 8.926…
Phase 4 N=128 Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
Skin Irritation
Primary: Area of Erythema and Elevated Responses of Skin to Product — 91; 68; 33; 42 participants
N/A N=37 A Photoxicity and Photoallergy Study of a Developmental Face Cream, Serum and Lotion
Skin Care
Primary: Percentage of Participants With Photo-initiated Potential Sensitization Reaction — 0; 0; 0; 0 Participants
N/A N=60 Effectiveness of Using an Oil Bath Additive
Xerosis Cutis
Primary: Transepidermal Water Loss (TEWL) in g/m2/h at the Left Mid Volar Forearm — 10.0; 11.9 g/m2/h — p=0.002
Phase 1 N=259 Contact Sensitization Potential of 828 Ointment
Healthy Volunteers
Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants
Phase 4 N=35 Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin.
Acne Prone Skin
Primary: Cutaneous Tolerability Based on Visual Inspection - Erythema — 29; 33; 30; 29 participants
Phase 1 N=59 Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment
Healthy
Primary: Frequency Distribution of Skin Irritation Scores — 39; 10; 3; 0 Scores on a scale
N/A N=149 The Use of Coconut Oil for the Prevention and Treatment of Diaper Dermatitis in the NICU Population
Dermatitis, Contact
Primary: The Number of Days Free From Diaper Dermatitis — 4.065; 4.274 Days
N/A N=58 Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT
Erythema · Sensitisation
Primary: Evidence of Erythema During the Challenge Phase for Omeza Collagen Matrix — 53; 49; 0; 4 Participants
Phase 4 N=162 Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face
Acne Vulgaris
Primary: Facial Irritation and Cutaneous Effects — 1.5; 5.4; 3.1; 7.8 Scores on a Scale
Phase 4 N=25 Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.
Acne Vulgaris
Primary: Assessment of Facial Irritation and Cutaneous Effects — 4.8; 3.9; 8.8; 6.7 Ordinal data treated as interval
Phase 4 N=26 Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face
Acne Vulgaris
Primary: Comparative Assessment of Facial Irritation and Cutaneous Effects. — 1.1; 2.7; 3.2; 6.2 Scores on a Scale
N/A N=150 A Study to Assess the Local Cutaneous and Ocular Tolerance of Three Developmental Facial Skin-care Formulations.
Skin Care
Primary: Number of Participants Determined by a Dermatologist to Have a Clinically Relevant Positive Outcome for Cutaneous Irritation After 21 Days of Product Use — 1; 0; 0…
N/A N=36 To Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facial Product in Healthy Participants
Skin Care
Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 2 — 0; 0 Score on scale
Phase 4 N=53 Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications
Acne Vulgaris
Primary: Skin Erythema (Redness) — 1.06; 1.18; 1.26; 1.34 Units on a scale — p=> 0.05
Phase 4 N=50 Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris
Acne Vulgaris
Primary: Number of Participants Satisfied and Very Satisfied With Regimen — 42 participants
N/A N=209 Repeated Insult Patch Test of Personal Lubricants
Erythema · Edema
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 0 participants
Phase 1 N=38 Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment
Healthy
Primary: Skin Reaction Score — 0.4; 0.5; 0.1; 0.4 units on a scale
N/A N=113 To Investigate the Cutaneous and Ocular Local Tolerance of Two Cosmetic Facial Cleanser in Healthy Females With Sensitive Skin
Skin Care
Primary: Frequency of Combined Dermatologist Score — 1; 1; 51; 55 Participants
N/A N=280 To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Facial Products
Skin Care
Primary: Percentage of Participants With Potential Sensitisation Reactions as Assessed by Dermatologist on Day 40 — 2; 1; 1; 0 Number of participants
Phase 3 N=732 A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)
Acne Vulgaris
Primary: Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA) — 20.3; 6.5 Percentage of subjects
N/A N=132 A Study to Evaluate of Cosmetic Benefit of a Moisturising Cream in People With Blemish Prone Skin
Skin Care
Primary: Change From Baseline in Corneometer Values at 8 Hours on Day 1 — 6.14; 2.63; 3.60 Arbitrary Corneometer unit — p=0.0128
Phase 4 N=48 A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne
Acne Vulgaris
Primary: Erythema (Redness) — 0.66; 0.91; 0.55; 0.74 units on a scale
N/A N=40 Coconut Oil vs. Commercial Ultrasound Gel In Obstetric Ultrasounds
Pregnancy, High Risk
Primary: Quality of Ultrasound Images — 76.05; 76.14; 75.18; 76.35 score on a scale
N/A N=11 A Pilot Clinical Trial Investigating the Effect of Cutaneous Cooling on Sebum Production
Acne
Primary: Percent Change in Sebum Production in Treated Sites as Compared to Baseline Using Sebutape Measurements. — -10.9; 6.9; 7.8; 45.0 Percent change from baseline
Phase 4 N=52 Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications
Acne Vulgaris
Primary: Skin Erythema (Redness) — 1.56; 1.89; 2.62; 2.65 Units on a scale — p=>0.05
Phase 3 N=825 Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face
Acne Vulgaris
Primary: Mean Percent Change From Baseline in the Papules and Pustules Lesion Count — 68.18; 63.56; 50.72 percentage of lesion change